{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T10:21:38Z","timestamp":1760955698582,"version":"3.41.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"36","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Dutch Ministry of Health"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.vaccine.2017.06.007","type":"journal-article","created":{"date-parts":[[2017,6,22]],"date-time":"2017-06-22T04:30:19Z","timestamp":1498105819000},"page":"4753-4760","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Adolescent meningococcal serogroup A, W and Y immune responses following immunization with quadrivalent meningococcal A, C, W and Y conjugate vaccine: Optimal age for vaccination"],"prefix":"10.1016","volume":"35","author":[{"given":"Mari\u00ebtte B.","family":"van Ravenhorst","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fiona R.M.","family":"van der Klis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debbie M.","family":"van Rooijen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth A.M.","family":"Sanders","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guy A.M.","family":"Berbers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2017.06.007_b0005","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1016\/S0140-6736(07)61016-2","article-title":"Epidemic meningitis, meningococcaemia, and Neisseria meningitidis","volume":"369","author":"Stephens","year":"2007","journal-title":"Lancet"},{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2017.06.007_b0010","doi-asserted-by":"crossref","first-page":"B26","DOI":"10.1016\/j.vaccine.2011.12.032","article-title":"The changing and dynamic epidemiology of meningococcal disease","volume":"30","author":"Halperin","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.06.007_b0015","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1093\/cid\/ciu601","article-title":"A decade of herd protection after introduction of meningococcal serogroup C conjugate vaccination","volume":"59","author":"Bijlsma","year":"2014","journal-title":"Clin Infect Dis: An Off Public Infect Dis Soc Am"},{"key":"10.1016\/j.vaccine.2017.06.007_b0020","doi-asserted-by":"crossref","first-page":"566","DOI":"10.3201\/eid1904.111799","article-title":"Description and nomenclature of Neisseria meningitidis capsule locus","volume":"19","author":"Harrison","year":"2013","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2017.06.007_b0025","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1478-7954-11-17","article-title":"Global epidemiology of invasive meningococcal disease","volume":"11","author":"Jafri","year":"2013","journal-title":"Populat Health Met"},{"key":"10.1016\/j.vaccine.2017.06.007_b0030","first-page":"505","article-title":"GlobalMeningococcalIEvolvingmeningococcalimmunization strategies","volume":"14","author":"Safadi","year":"2015","journal-title":"Exp Rev Vacc"},{"key":"10.1016\/j.vaccine.2017.06.007_b0035","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S1473-3099(14)70806-0","article-title":"Epidemiology of invasive meningococcal disease in the Netherlands, 1960\u20132012: an analysis of national surveillance data","volume":"14","author":"Bijlsma","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2017.06.007_b0040","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/01.inf.0000195594.41449.c6","article-title":"Protection from routine vaccination at the age of 14 months with meningococcal serogroup C conjugate vaccine in the Netherlands","volume":"25","author":"de Greeff","year":"2006","journal-title":"Pediat Infect Dis J"},{"key":"10.1016\/j.vaccine.2017.06.007_b0045","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.4161\/hv.28206","article-title":"Meningococcal serogroup Y emergence in Europe: high importance in some European regions in 2012","volume":"10","author":"Broker","year":"2014","journal-title":"Human Vacc Immunotherap"},{"key":"10.1016\/j.vaccine.2017.06.007_b0050","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1080\/21645515.2015.1051276","article-title":"Meningococcal serogroup Y disease in Europe: continuation of high importance in some European regions in 2013","volume":"11","author":"Broker","year":"2015","journal-title":"Human Vacc Immunotherapeut"},{"key":"10.1016\/j.vaccine.2017.06.007_b0055","doi-asserted-by":"crossref","first-page":"E454","DOI":"10.33321\/cdi.2016.40.50","article-title":"Rise in invasive serogroup W meningococcal disease in Australia 2013\u20132015","volume":"40","author":"Martin","year":"2016","journal-title":"Commun Dis Intell Quart Rep"},{"key":"10.1016\/j.vaccine.2017.06.007_b0060","doi-asserted-by":"crossref","unstructured":"Campbell H, Saliba V, Borrow R, Ramsay M, Ladhani SN. Targeted vaccination of teenagers following continued rapid endemic expansion of a single meningococcal group W clone (sequence type 11 clonal complex), United Kingdom 2015. Euro surveillance: bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin; 2015.p. 20.","DOI":"10.2807\/1560-7917.ES2015.20.28.21188"},{"key":"10.1016\/j.vaccine.2017.06.007_b0065","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1093\/cid\/ciu881","article-title":"Increase in Endemic Neisseria meningitidis Capsular Group W Sequence Type 11 Complex Associated With Severe Invasive Disease in England and Wales","volume":"60","author":"Ladhani","year":"2015","journal-title":"Clin Infect Dis: An Off Public Infect Dis Soc Am"},{"key":"10.1016\/j.vaccine.2017.06.007_b0070","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1017\/S0950268814001149","article-title":"Serogroup W meningococcal disease: global spread and current affect on the Southern Cone in Latin America","volume":"142","author":"Abad","year":"2014","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.vaccine.2017.06.007_b0075","unstructured":"Updated recommendations for use of meningococcal conjugate vaccines --- Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morbidity and mortality weekly report. 2011;60:72-6."},{"key":"10.1016\/j.vaccine.2017.06.007_b0080","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1136\/archdischild-2015-308928","article-title":"Enter B and W: two new meningococcal vaccine programmes launched","volume":"101","author":"Ladhani","year":"2016","journal-title":"Arch Dis Childhood"},{"key":"10.1016\/j.vaccine.2017.06.007_b0085","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(02)08679-8","article-title":"Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination","volume":"359","author":"Maiden","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2017.06.007_b0090","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S1473-3099(10)70251-6","article-title":"Meningococcal carriage by age: a systematic review and meta-analysis","volume":"10","author":"Christensen","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2017.06.007_b0095","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jinf.2015.02.006","article-title":"Meningococcal carriage in adolescents in the United Kingdom to inform timing of an adolescent vaccination strategy","volume":"71","author":"Jeppesen","year":"2015","journal-title":"J Infect"},{"key":"10.1016\/j.vaccine.2017.06.007_b0100","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1128\/CDLI.4.2.156-167.1997","article-title":"Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group","volume":"4","author":"Maslanka","year":"1997","journal-title":"Clin Diagnost Lab Immunol"},{"key":"10.1016\/j.vaccine.2017.06.007_b0105","doi-asserted-by":"crossref","first-page":"e55486","DOI":"10.1371\/journal.pone.0055486","article-title":"Seroprevalence of bactericidal, specific IgG antibodies and incidence of meningitis due to group A Neisseria meningitidis by age in Burkina Faso 2008","volume":"8","author":"Trotter","year":"2013","journal-title":"PloS one"},{"key":"10.1016\/j.vaccine.2017.06.007_b0110","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1128\/CVI.00549-10","article-title":"Measurement of functional anti-meningococcal serogroup a activity using strain 3125 as the target strain for serum bactericidal assay","volume":"18","author":"Poolman","year":"2011","journal-title":"Clin Vacc Immunol: CVI"},{"key":"10.1016\/j.vaccine.2017.06.007_b0115","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1128\/IAI.69.3.1568-1573.2001","article-title":"Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection","volume":"69","author":"Borrow","year":"2001","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.06.007_b0120","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/j.vaccine.2005.01.051","article-title":"Meningococcal surrogates of protection\u2013serum bactericidal antibody activity","volume":"23","author":"Borrow","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.06.007_b0125","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1128\/CDLI.10.5.780-786.2003","article-title":"Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England","volume":"10","author":"Andrews","year":"2003","journal-title":"Clin Diagnost Lab Immunol"},{"key":"10.1016\/j.vaccine.2017.06.007_b0130","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1128\/CVI.00364-08","article-title":"Simultaneous detection of Haemophilus influenzae type b polysaccharide-specific antibodies and Neisseria meningitidis serogroup A, C, Y, and W-135 polysaccharide-specific antibodies in a fluorescent-bead-based multiplex immunoassay","volume":"16","author":"de Voer","year":"2009","journal-title":"Clin Vacc Immunol: CVI"},{"key":"10.1016\/j.vaccine.2017.06.007_b0135","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1128\/CVI.00478-07","article-title":"Development of a fluorescent-bead-based multiplex immunoassay to determine immunoglobulin G subclass responses to Neisseria meningitidis serogroup A and C polysaccharides","volume":"15","author":"de Voer","year":"2008","journal-title":"Clin Vacc Immunol: CVI"},{"key":"10.1016\/j.vaccine.2017.06.007_b0140","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1128\/CDLI.11.2.272-279.2004","article-title":"Development and evaluation of a tetraplex flow cytometric assay for quantitation of serum antibodies to Neisseria meningitidis serogroups A, C, Y, and W-135","volume":"11","author":"Lal","year":"2004","journal-title":"Clin Diagnost Lab Immunol"},{"key":"10.1016\/j.vaccine.2017.06.007_b0145","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/1471-2334-13-116","article-title":"Immune response, antibody persistence, and safety of a single dose of the quadrivalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine in adolescents and adults: results of an open, randomised, controlled study","volume":"13","author":"Borja-Tabora","year":"2013","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2017.06.007_b0150","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.vaccine.2008.08.075","article-title":"Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15\u201325 years","volume":"27","author":"Ostergaard","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.06.007_b0155","doi-asserted-by":"crossref","first-page":"e12144","DOI":"10.1371\/journal.pone.0012144","article-title":"Immunity against Neisseria meningitidis serogroup C in the Dutch population before and after introduction of the meningococcal c conjugate vaccine","volume":"5","author":"de Voer","year":"2010","journal-title":"PloS One"},{"key":"10.1016\/j.vaccine.2017.06.007_b0160","doi-asserted-by":"crossref","first-page":"e203","DOI":"10.1097\/INF.0b013e318224fb14","article-title":"Persistence of serum bactericidal antibody one year after a booster dose of either a glycoconjugate or a plain polysaccharide vaccine against serogroup C Neisseria meningitidis given to adolescents previously immunized with a glycoconjugate vaccine","volume":"30","author":"de Whalley","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2017.06.007_b0165","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1136\/archdischild-2013-303893","article-title":"Long-term seroprotection after an adolescent booster meningococcal serogroup C vaccination","volume":"98","author":"de Whalley","year":"2013","journal-title":"Arch Disease Childhood"},{"key":"10.1016\/j.vaccine.2017.06.007_b0170","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1086\/527401","article-title":"Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity","volume":"197","author":"Maiden","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.06.007_b0175","unstructured":"Ravenhorst MB, Bijlsma MW, van Houten MA, Struben VM, Anderson AS, Eiden J, et al. Meningococcal carriage in Dutch adolescents and young adults; A cross-sectional and longitudinal cohort study. Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases; 2017."},{"key":"10.1016\/j.vaccine.2017.06.007_b0180","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1093\/infdis\/135.1.94","article-title":"Cross-antigenicity and immunogenicity between capsular polysaccharides of group C Neisseria meningitidis and of Escherichia coli K92","volume":"135","author":"Glode","year":"1977","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.06.007_b0185","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1128\/IAI.13.6.1654-1662.1976","article-title":"Bacillus pumilus polysaccharide cross-reactive with meningococcal group A polysaccharide","volume":"13","author":"Vann","year":"1976","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.06.007_b0190","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1016\/S0140-6736(14)60842-4","article-title":"Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial","volume":"384","author":"Read","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2017.06.007_b0195","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.vaccine.2013.09.034","article-title":"Evaluation of serogroup C and ACWY meningococcal vaccine programs: projected impact on disease burden according to a stochastic two-strain dynamic model","volume":"33","author":"Vickers","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.06.007_b0200","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1056\/NEJM198608213150807","article-title":"Response to oligosaccharide-protein conjugate vaccine against Hemophilus influenzae b in two patients with IgG2 deficiency unresponsive to capsular polysaccharide vaccine","volume":"315","author":"Insel","year":"1986","journal-title":"New Engl J Med"},{"key":"10.1016\/j.vaccine.2017.06.007_b0205","doi-asserted-by":"crossref","first-page":"e23497","DOI":"10.1371\/journal.pone.0023497","article-title":"Age-related immunity to meningococcal serogroup C vaccination: an increase in the persistence of IgG2 correlates with a decrease in the avidity of IgG","volume":"6","author":"de Voer","year":"2011","journal-title":"PloS One"},{"key":"10.1016\/j.vaccine.2017.06.007_b0210","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1046\/j.1365-3024.1999.00197.x","article-title":"Echinococcus granulosus human infection stimulates low avidity anticarbohydrate IgG2 and high avidity antipeptide IgG4 antibodies","volume":"21","author":"Sterla","year":"1999","journal-title":"Parasite Immunol"},{"key":"10.1016\/j.vaccine.2017.06.007_b0215","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1128\/CDLI.10.5.802-807.2003","article-title":"Negative immunodiffusion test results obtained with sera of paracoccidioidomycosis patients may be related to low-avidity immunoglobulin G2 antibodies directed against carbohydrate epitopes","volume":"10","author":"Neves","year":"2003","journal-title":"Clin Diagnost Lab Immunol"},{"key":"10.1016\/j.vaccine.2017.06.007_b0220","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1128\/CVI.13.4.507-510.2006","article-title":"Immunoglobulin G subclass response to a meningococcal quadrivalent polysaccharide-diphtheria toxoid conjugate vaccine","volume":"13","author":"Findlow","year":"2006","journal-title":"Clin Vacc Immunol: CVI"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17307843?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17307843?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T22:26:24Z","timestamp":1750371984000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X17307843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":44,"journal-issue":{"issue":"36","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["S0264410X17307843"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.06.007","relation":{},"ISSN":["0264-410X"],"issn-type":[{"type":"print","value":"0264-410X"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adolescent meningococcal serogroup A, W and Y immune responses following immunization with quadrivalent meningococcal A, C, W and Y conjugate vaccine: Optimal age for vaccination","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.06.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}